Novavax Stock Rockets over 200% as It Signs COVID-19 License Deal with Sanofi, Removes Doubt About Business Viability
(Reuters) - Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with $Sanofi(GCVRZ)$ for COVID-19 vaccines in exchange for a st
Wall Street Analysts See a 71.71% Upside in Phunware (PHUN): Can the Stock Really Move This High?
Shares of Phunware have gained 0.4% over the past four weeks to close the last trading session at $9.51, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $16.33 indicates a potential upside of 71.7%.The mean estimate comprises three short-term price targets with a standard deviation of $4.04. While the lowest estimate of $12 indicates a 26.2% increase from the current price level, the most optimistic analyst expects the stock to surge 110.3% to reach $20. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always b